Holen Sie sich die Stockscreener-App
2.66
1.14%
0.03
Handel nachbörslich:
2.68
0.02
+0.75%
Schlusskurs vom Vortag:
$2.63
Offen:
$2.59
24-Stunden-Volumen:
42,494
Relative Volume:
0.38
Marktkapitalisierung:
$85.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-10.74M
KGV:
-7.8235
EPS:
-0.34
Netto-Cashflow:
$-6.53M
1W Leistung:
-7.96%
1M Leistung:
-14.19%
6M Leistung:
-13.92%
1J Leistung:
-17.65%
1-Tages-Spanne:
$2.58
$2.83
1-Wochen-Bereich:
$2.58
$3.01
52-Wochen-Spanne:
$2.07
$4.20
Anixa Biosciences Inc Stock (ANIX) Company Profile
Firmenname
Anixa Biosciences Inc
Sektor
Branche
Telefon
408-708-9808
Adresse
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Vergleichen Sie ANIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.66 | 85.64M | 0 | -10.74M | -6.53M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.34 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.16 | 78.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.43 | 35.27B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.74 | 30.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.71 | 26.37B | 3.32B | -860.46M | -1.04B | -8.32 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-12-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-04-12 | Eingeleitet | H.C. Wainwright | Buy |
Anixa Biosciences Inc Aktie (ANIX) Neueste Nachrichten
Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties - BioSpace
Anixa Biosciences (ANIX) to Release Earnings on Tuesday - Defense World
Anixa Biosciences to Present at the 18th Annual European Life Sc - GuruFocus.com
Anixa Biosciences : to Hold Conference Call to Discuss Outlook for 2019 -January 16, 2019 at 07:31 am EST - Marketscreener.com
Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th - PR Newswire
Spotlight On February 2025's Promising Penny Stocks - Yahoo Finance
Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial - PR Newswire
Can Anixa's Ovarian Cancer CAR-T Therapy Advance After Successful 10-Fold Dose Escalation? - StockTitan
Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox New - GuruFocus.com
Can This Breast Cancer Vaccine Change Prevention Forever? Anixa's Trial Shows 70% Response Rate - StockTitan
Anixa Biosciences Featured in Breaking Cancer News Article on No - GuruFocus.com
Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer - PR Newswire
HC Wainwright Issues Optimistic Forecast for ANIX Earnings - Defense World
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
HC Wainwright Reaffirms “Buy” Rating for Anixa Biosciences (NASDAQ:ANIX) - Armenian Reporter
Anixa Biosciences’ (ANIX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Anixa Biosciences Announces Approval of Protocol Amendment for O - GuruFocus.com
Anixa Biosciences expands CAR-T therapy trial for ovarian cancer - Investing.com
Anixa Biosciences expands CAR-T therapy trial for ovarian cancer By Investing.com - Investing.com South Africa
Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial - PR Newswire
Major Breakthrough: Anixa's Ovarian Cancer Trial ExpandsSecond CAR-T Dose Now Available for Patients - StockTitan
Anixa Biosciences director Lewis Titterton buys $6,020 worth of stock - MSN
Anixa Biosciences director Lewis H. Titterton Jr. buys $15,540 in stock - MSN
Short Interest in Anixa Biosciences, Inc. (NASDAQ:ANIX) Expands By 13.7% - MarketBeat
Revolutionary Cancer Treatment Alert: Anixa's Dual-Attack Strategy Against Ovarian and Breast Cancer Unveiled - StockTitan
Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview - PR Newswire
Anixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum - sharewise
Anixa Biosciences Inc (ANIX) Stock: A Closer Look at the Market Potential - The News Heater
Contrasting Eterna Therapeutics (NASDAQ:ERNA) and Anixa Biosciences (NASDAQ:ANIX) - Defense World
Breakthrough Cancer Prevention: Anixa CEO Reveals Novel Vaccine Strategy Against Triple-Negative Breast Cancer - StockTitan
Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention - PR Newswire
Insider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Purchases 5,000 Shares of Stock - MarketBeat
Anixa biosciences director Arnold Baskies buys $14,100 in stock - MSN
Insider Buying: Arnold Baskies Acquires Additional Shares of Ani - GuruFocus.com
Anixa biosciences director Arnold Baskies buys $14,100 in stock By Investing.com - Investing.com UK
Anixa Biosciences director Titterton buys $8,820 in common stock - MSN
Anixa Biosciences director Titterton buys $8,820 in common stock By Investing.com - Investing.com Australia
Anixa Biosciences’ (ANIX) Buy Rating Reiterated at D. Boral Capital - Defense World
Anixa Biosciences reports progress in cancer vaccine trials - MSN
Anixa Biosciences director Lewis Titterton buys $6,020 worth of stock By Investing.com - Investing.com Australia
Insider Buying: Titterton Lewis H jr Acquires Additional Shares of Anixa Biosciences Inc (ANIX) - GuruFocus.com
Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Purchases $15,540.00 in Stock - MarketBeat
Finanzdaten der Anixa Biosciences Inc-Aktie (ANIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.14%
2.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):